Notice: This company has been marked as potentially delisted and may not be actively trading. Lumos Pharma (LUMO) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for LUMO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lumos Pharma and its competitors. Enter your email to sign up for newsletter Sign Up LUMO Analyst Ratings Over TimeTypeCurrent Forecast1/23/24 to 1/22/251 Month Ago12/24/23 to 12/23/243 Months Ago10/25/23 to 10/24/241 Year Ago1/23/23 to 1/23/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)3 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.63$8.63$8.63$18.00Forecasted Upside98.73% Upside98.73% Upside98.28% Upside527.18% UpsideConsensus RatingBuyBuyBuyBuy LUMO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History LUMO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Lumos Pharma Stock vs. The CompetitionTypeLumos PharmaMedical CompaniesS&P 500Consensus Rating Score 3.00 2.82 2.52Consensus RatingBuyModerate BuyModerate BuyPredicted Upside98.73% Upside24,997.56% Upside11.39% UpsideNews Sentiment RatingVery Positive NewsSee Recent LUMO NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/8/2024HC Wainwright2 of 5 starsE. WhiteSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.25 ➝ $4.25-2.30%9/24/2024EF Hutton Acquisition Co. I1 of 5 starsJ. KolbertSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/2/2024Oppenheimer3 of 5 stars Lower TargetOutperform ➝ Outperform$16.00 ➝ $13.00+606.56%8/22/2023Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$10.00+261.01%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:09 PM ET. LUMO Forecast - Frequently Asked Questions What is Lumos Pharma's forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Lumos Pharma is $8.63, with a high forecast of $13.00 and a low forecast of $4.25. Should I buy or sell Lumos Pharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There is currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUMO shares. Does Lumos Pharma's stock price have much upside? According to analysts, Lumos Pharma's stock has a predicted upside of 98.73% based on their 12-month stock forecasts. What analysts cover Lumos Pharma? Lumos Pharma has been rated by research analysts at HC Wainwright in the past 90 days. Do Wall Street analysts like Lumos Pharma more than its competitors? Analysts like Lumos Pharma more than other "medical" companies. The consensus rating for Lumos Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LUMO compares to other companies. Stock Forecasts and Research Tools Related Companies InflaRx Stock Forecast FitLife Brands Stock Forecast Adaptimmune Therapeutics Stock Forecast Puma Biotechnology Stock Forecast Corbus Pharmaceuticals Stock Forecast Fate Therapeutics Stock Forecast Biomea Fusion Stock Forecast Kyverna Therapeutics Stock Forecast INmune Bio Stock Forecast Ventyx Biosciences Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:LUMO) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget 99.999% of Stocks… Do This insteadThis might sound crazy to say... But FORGET most stocks. Because I have a different strategy... One t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
